Henrik Blou
Directeur Général chez GUBRA A/S
Fortune : 22 M $ au 30/04/2024
Profil
Henrik Blou is the founder of MycoTeQ A, which was founded in 2006.
He held the title of Chief Operating Officer from 2009 to 2010.
Mr. Blou is currently the Chief Executive Officer at Gubra.
A since 2016 and also holds the position of Director at Dansk Biotek.
In the past, he was the Chief Executive Officer at Aros Pharma ApS and Director of Business Development at EpiTherapeutics ApS.
Mr. Blou also worked as a Management Consultant at McKinsey & Co., Inc. in 2006.
He graduated from the Technical University of Denmark.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GUBRA A/S
3,10% | 20/03/2023 | 506 499 ( 3,10% ) | 22 M $ | 30/04/2024 |
Postes actifs de Henrik Blou
| Sociétés | Poste | Début |
|---|---|---|
| GUBRA A/S | Directeur Général | 01/06/2016 |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Directeur/Membre du Conseil | - |
Anciens postes connus de Henrik Blou
| Sociétés | Poste | Fin |
|---|---|---|
Aros Pharma ApS
 Aros Pharma ApS Pharmaceuticals: MajorHealth Technology Aros Pharma ApS is a holding company that develops medicine targeting unmet needs within pain relief, infectious disease, inflammation, respiratory diseases, and immuno-suppressed patients. It is a biotech company that focuses on clinical development of a novel therapy for the treatment of gastrointestinal pain. The firm is developing a new pain relief therapy based on a small molecule (PPC-5650) that is a specific inhibitor of the ASIC 1a receptor (Acid Sensing Ion Channel subtype 1a). Its therapy is currently being tested in two phase I trials targeting pain in patients who suffer from Irritable Bowel Syndrome (IBS) or non-erosive Gastroesophageal Reflux Disease (NERD). The company was founded in 2009 and is headquartered in Copenhagen, Denmark. | Directeur Général | - |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Corporate Officer/Principal | - |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2006 |
MycoTeQ A/S
 MycoTeQ A/S Pharmaceuticals: MajorHealth Technology MycoTeQ is working to ease the discovery process for the pharmaceutical industry in order to ensure a steady flow of new chemical entities into the pipelines of this industry. The aspiration of MycoTeQ is to build a healthy business and become the world leading external provider of new chemical entities from micro fungi. In order to succeed on these ambitious targets MycoTeQ will adhere to the highest professional and scientific standards and seek to build strong and long-lasting relationships with its partners and customers. The company was founded in October 2006 and is headquartered in Copenhagen, Denmark. | Directeur Général | - |
Formation de Henrik Blou
| Technical University of Denmark | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GUBRA A/S | Commercial Services |
| Entreprise privées | 5 |
|---|---|
MycoTeQ A/S
MycoTeQ A/S Pharmaceuticals: MajorHealth Technology MycoTeQ is working to ease the discovery process for the pharmaceutical industry in order to ensure a steady flow of new chemical entities into the pipelines of this industry. The aspiration of MycoTeQ is to build a healthy business and become the world leading external provider of new chemical entities from micro fungi. In order to succeed on these ambitious targets MycoTeQ will adhere to the highest professional and scientific standards and seek to build strong and long-lasting relationships with its partners and customers. The company was founded in October 2006 and is headquartered in Copenhagen, Denmark. | Health Technology |
EpiTherapeutics ApS
EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Aros Pharma ApS
Aros Pharma ApS Pharmaceuticals: MajorHealth Technology Aros Pharma ApS is a holding company that develops medicine targeting unmet needs within pain relief, infectious disease, inflammation, respiratory diseases, and immuno-suppressed patients. It is a biotech company that focuses on clinical development of a novel therapy for the treatment of gastrointestinal pain. The firm is developing a new pain relief therapy based on a small molecule (PPC-5650) that is a specific inhibitor of the ASIC 1a receptor (Acid Sensing Ion Channel subtype 1a). Its therapy is currently being tested in two phase I trials targeting pain in patients who suffer from Irritable Bowel Syndrome (IBS) or non-erosive Gastroesophageal Reflux Disease (NERD). The company was founded in 2009 and is headquartered in Copenhagen, Denmark. | Health Technology |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Commercial Services |
